Bioxcel Therapeutics BTAI 深 沪
等待开盘 09-16 09:30:00 美东时间
3.17
+0.060
+1.93%
华盛通- 最 高3.19
- 今 开3.00
- 成交量 208.49万股
- 最 低 2.91
- 昨 收 3.11
- 总市值 4614.47万
- 52周最高 13.28
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.17
- 委 比 -82.03%
- 总股本 1455.67万
- 历史最高 1144.00
- 量 比 0.73
- 振 幅 9.00%
- 历史最低 2.56
- 每 手 1
- 风险率 3.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Bioxcel Therapeutics Files Current Report on Form 8-K
Bioxcel Therapeutics ( ($BTAI) ) has provided an announcement. Bioxcel Therapeu...
09-15 23:09
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
09-15 11:13
Mizuho Maintains Neutral on BioXcel Therapeutics, Raises Price Target to $4
Mizuho analyst Graig Suvannavejh maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Neutral and raises the price target from $2 to $4.
09-12 19:57
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
BioXcel's Phase 3 trial shows BXCL501 effectively reduces agitation in bipolar and schizophrenia patients, supporting its at-home treatment use.
09-11 03:08
BioXcel Therapeutics Reports Positive Phase 3 Trial Results
Bioxcel Therapeutics ( ($BTAI) ) has issued an update. On September 10, 2025, B...
09-10 18:59
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BioXcel Therapeutics' CEO, Vimal Mehta, Ph.D., will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 4:30 p.m. ET. The presentation will be available via webcast. BioXcel Therapeutics utilizes AI to develop innovative medicines in neuroscience and immuno-oncology, focusing on drug re-innovation to identify new therapeutic indications. The event webcast and additional information c...
09-04 11:00
BioXcel’s Phase 3 Trial Success for BXCL501
Bioxcel Therapeutics ( ($BTAI) ) has shared an update. On August 27, 2025, BioX...
08-27 19:28
UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®
BioXcel Therapeutics announced that its SERENITY At-Home trial met its primary endpoint, demonstrating that BXCL501 is well-tolerated and safe for treating agitation episodes at home in patients with bipolar disorders or schizophrenia. The trial, which involved over 2,400 episodes, showed consistent benefits with repeated dosing and no serious adverse events. BioXcel plans to submit an sNDA in Q1 2026 to expand the label for at-home use, addressi...
08-27 12:00
Bioxcel Therapeutics Announces It Will Host An Investor Call And Live Webcast On August 27, 2025, At 8 A.M. Et To Present Topline Data From Its Serenity At-Home Phase 3 Trial
BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it will host an investor call and
08-27 04:02
Bioxcel Therapeutics Files Prospectus for $80M Share Sale
The latest update is out from Bioxcel Therapeutics ( ($BTAI) ). On April 3, 202...
08-19 05:52
